Summary:
Daxor Corporation has expanded its blood volume analysis (BVA) technology into three new hospitals, highlighting growing demand for its lab service and on-site analyzer to improve patient care and reduce healthcare costs.

Takeaways:

  • Daxor’s CLIA-certified ezBVA Lab service offers next-day blood volume analysis, driving adoption across inpatient and outpatient cardiology care.
  • Three major hospitals across Tennessee, Arkansas, and the Southwest U.S. have recently integrated Daxor’s BVA technology into their clinical programs.
  • The company anticipates continued sales growth through 2025 as clinicians increasingly rely on BVA for fluid management in heart failure and cardiovascular care.

Daxor Corporation, a global provider of blood volume measurement technology, announces the expansion of its blood volume analysis (BVA) technology into three new hospitals, a testament to the growing recognition of BVA’s essential role in improving lives and reducing healthcare costs.

Growth Driven by State of the Art Lab Service and On-Demand Analysis Results

This growth is driven by a combination of Daxor’s state-of-the-art CLIA-certified ezBVA Lab service, which delivers on-demand, next-day blood volume analysis results, and an on-site placement of its blood volume analyzer. The company expects accelerated sales growth to continue throughout 2025 as clinicians increasingly embrace the benefits of BVA for optimizing fluid management decisions. 

Daxor’s Recent Blood Volume Analysis Wins

The company has added its blood volume analysis technology in three facilities:

• Expansion into a key Tennessee medical center within a large integrated community healthcare system in the Appalachian Highlands, is adopting ezBVA Lab services for inpatient and outpatient cardiology applications
• A major hospital serving Arkansas is integrating BVA with an on-site analyzer to enhance its advanced heart care programs for both inpatient and outpatient settings
• A leading referral hospital serving Arizona, Nevada and Utah is utilizing Daxor’s ezBVA Lab service for its advanced heart failure patients, both inpatient and outpatient

“We are incredibly proud to announce the expansion of our BVA technology into three renowned facilities as a testament to the growing recognition of BVA’s pivotal role in improving lives and reducing healthcare costs,” says Michael Feldschuh, Daxor Corporation CEO and president. “This momentum, driven by the increasing integration of our ezBVA Lab Service and on-site analyzers, underscores our commitment to providing clinicians, regardless of location, with precise tools to guide optimal fluid management.”

Featured Image: Iryna Kushnarova | Dreamstime.com